# Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

> **NCT06702826** · PHASE2 · RECRUITING · sponsor: **Rongrong Zhou** · enrollment: 20 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Brain Metastases
- Stereotactic Radiation
- Immunotherapy

## Interventions

- **DRUG:** Cadonilimab combined with SRS

## Key facts

- **NCT ID:** NCT06702826
- **Lead sponsor:** Rongrong Zhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06702826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06702826, "Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06702826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*